Overexpression of promyelocytic leukemia protein and alteration of PML nuclear bodies in early stage of hepatocarcinogenesis

被引:9
|
作者
Yoon, GS [1 ]
Yu, E [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol,Songpa Gu, Seoul 138736, South Korea
关键词
leukemia; promyelocytic; nuclear body; carcinoma; hepatocellular; dysplastic nodule; liver cirrhosis; hepatitis B virus;
D O I
10.3346/jkms.2001.16.4.433
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Promyelocytic leukemia protein (PML) is a major component of PML nuclear bodies (PML NBs). Fusion of promyelocytic leukemia gene (PML) with retinoic acid receptor a gene with the t (15;17) translocation causes disassembly of PML NBs, leading to development of acute promyelocytic leukemia. In contrast, PML overexpression as well as different morphological changes of PML NBs were described in a few solid tumors. In this study, the expression of PML through the multistep hepatocarcinogenesis was analyzed in 95 cases of human hepatocellular carcinomas (HCCs) for comparison along with dysplastic nodules (DNs) and background liver cirrhosis (LC) or chronic hepatitis by immunohistochemistry and immunoblot. In addition, cases of HCCs were further evaluated according to their histologic grade and etiology. The amount of PML as well as the number and size of PML NBs increased gradually through the progression from LC, DNs to HCCs. The overexpression of ll in HCCs was much more closely associated with HBV infection than HCV infection or alcoholic liver disease. The PML expression, however, was not correlated with histologic grade of HCCs. These results suggest that PML is involved in the early stage of multistep hepatocarcinogenesis, and HBV infection may be associated with the overexpression of PML and the morphological alteration of PML NBs.
引用
收藏
页码:433 / 438
页数:6
相关论文
共 50 条
  • [1] Pondering the promyelocytic leukemia protein (PML) puzzle: Possible functions for PML nuclear bodies
    Borden, KLB
    MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (15) : 5259 - 5269
  • [2] Targeting Promyelocytic Leukemia Protein: A Means to Regulating PML Nuclear Bodies
    Reineke, Erin L.
    Kao, Hung-Ying
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2009, 5 (04): : 366 - 376
  • [3] Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA
    Boisvert, FM
    Hendzel, MJ
    Bazett-Jones, DP
    JOURNAL OF CELL BIOLOGY, 2000, 148 (02): : 283 - 292
  • [4] Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies
    Hirano, Seishiro
    Udagawa, Osamu
    PLOS ONE, 2022, 17 (05):
  • [5] Acute promyelocytic leukemia, arsenic, and PML bodies
    de The, Hugues
    Le Bras, Morgane
    Lallemand-Breitenbach, Valerie
    JOURNAL OF CELL BIOLOGY, 2012, 198 (01): : 11 - 21
  • [6] A Bayesian Network Model of Proteins' Association with Promyelocytic Leukemia (PML) Nuclear Bodies
    Boden, Mikael
    Dellaire, Graham
    Burrage, Kevin
    Bailey, Timothy L.
    JOURNAL OF COMPUTATIONAL BIOLOGY, 2010, 17 (04) : 617 - 630
  • [7] Role of intrinsically disordered regions of promyelocytic leukemia (PML) protein in the formation of PML-bodies
    Fefilova, A.
    Fonin, A.
    Silonov, S.
    Stepananeko, O.
    Gavrilova, A.
    Kuznetsova, I.
    Turoverov, K.
    FEBS OPEN BIO, 2022, 12 : 73 - 73
  • [8] Nucleoli and Promyelocytic Leukemia Protein (PML) bodies are phase separated nuclear protein quality control compartments for misfolded proteins
    Mediani, L.
    Guillen-Boixet, J.
    Alberti, S.
    Carra, S.
    MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (06)
  • [9] PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?
    Brown, Nicola J. M.
    Ramalho, Michal
    Pedersen, Eva W.
    Moravcsik, Eva
    Solomon, Ellen
    Grimwade, David
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 1684 - 1707
  • [10] Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B
    Wang, Chao
    Su, Li De
    Shao, Yi Ming
    Chen, Wei Zhong
    Bu, Na
    Hao, Rui
    Ma, Li Ya
    Hussain, Liaqat
    Lu, Xiao Yang
    Wang, Qian Qian
    Naranmandura, Hua
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 384